<DOC>
	<DOCNO>NCT00164463</DOCNO>
	<brief_summary>This substudy TBTC Studies 27 28 compare 1 ) pharmacokinetics moxifloxacin alone versus moxifloxacin administer rifampin healthy volunteer 2 ) pharmacokinetics moxifloxacin among patient tuberculosis treat multidrug therapy ( isoniazid ethambutol , rifampin , pyrazinamide ) healthy volunteer receive moxifloxacin plus rifampin . It also evaluate association polymorphism MDR1 genotype ( P-glycoprotein ) rifampin pharmacokinetic parameter , effect polymorphism MDR1 genotype and/or rifampin pharmacokinetics isoniazid pharmacokinetic parameter adjust N-acetyltransferase genotype ( NAT2 ) , determines multivariate regression analyse association moxifloxacin rifampin pharmacokinetic parameter marker tuberculosis disease severity include covariates two-month culture positivity , cavitary lung disease , Body Mass Index , weight , duration study treatment prior PK , co-morbidities C-reactive protein . Healthy volunteer TB patient receive frequent schedule blood draw 24 hour period ingest dose TB drug .</brief_summary>
	<brief_title>TBTC Study 27/28 PK : Moxifloxacin Pharmacokinetics During TB Treatment</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>For Healthy Volunteers : Provision inform consent study . Age &gt; 18 year . Willingness available 2 week DOT . Willingness admit GCRC hospital two occasion . Women childbearing potential must agree practice adequate method birth control . Barrier method contraception abstinence sexual activity satisfactory method . Willingness HIV test do documented result available . ( A prior negative result must obtain within one year consist negative HIV ELISA . A positive result must positive HIV ELISA Western Blot , plasma HIV PCR RNA level great 5000 copies/ml ) . Laboratory screening ( already available ) within 30 day first PK admission : Serum potassium within normal limit Hematocrit &gt; 35 % Absolute neutrophil count &gt; 1000 /mm3 AST &lt; 3 time upper limit normal Bilirubin &lt; 2 time upper limit normal Creatinine &lt; 2 time upper limit normal Eligible enrol medical health care sponsor United States federal government ( Veterans Administration enrollment Priority 1 7 , VHA Directive 2003003 ) . For Patients Tuberculosis Enrolled TBTC Study 27 Study 28 : Any patient enrol TBTC Study 27 Study 28 receive daily ( 57 day per week ) regimen . Provision inform consent study . Willingness admit GCRC hospital one occasion . For Healthy Volunteers : Karnofsky score less 90 Pregnancy breastfeeding . ( A negative pregnancy test require woman childbearing potential within 14 day first dose moxifloxacin . ) Known allergy fluoroquinolone rifamycin antibiotic Current plan therapy study drug unacceptable interaction rifampin History prolong QT syndrome current plan therapy quinidine , procainamide , amiodarone , sotalol , ziprasidone period administration moxifloxacin one week treatment For Patients Tuberculosis Enrolled TBTC Study 27 Study 28 : Severe anemia define hematocrit le 25 % ( recent value , measure within 30 day PK study ) . History severe liver disease classify Child Pugh Class C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>TB</keyword>
</DOC>